Table 3.
The comparison of clinical findings of patients with requiring hospitalization and others
| Patients who were ambulatory (n = 89) | Patients who were hospitalized (n = 24) | P value | |
|---|---|---|---|
| Female/male, n | 57/32 | 15/9 | 0.53 |
| The mean of age (years) | 14.4 | 11.5 | 0.44 |
| Distribution of rheumatic disease, n | 0.27 | ||
| Juvenile idiopathic arthritis | 51 | 12 | |
| Systemic autoinflammatory diseases | 29 | 6 | |
| Vasculitis | 7 | 3 | |
| Connective tissue diseases | 2 | 3 | |
| The mean ± SD duration of primary rheumatic disease (months) | 41.5 ± 43.5 | 35.2 ± 45.04 | 0.30 |
| Comorbid disease, n | 14 | 5 | 0.42 |
| Usage of corticosteroids, n | 17 | 10 | 0.03 |
| Median dose of steroid, mg/kg | 0.16 (0.05–2) | 0.15 (0.02–0.6) | 0.34 |
| Usage of DMARD, n | 38 | 8 | 0.27 |
| Distribution of biologic drugs, n | 0.33 | ||
| Canakinumab | 26 | 9 | |
| Infliximab | 9 | 1 | |
| Adalimumab | 22 | 4 | |
| Etanercept | 16 | 3 | |
| Tocilizumab | 8 | 1 | |
| Anakinra | 2 | 2 | |
| Rituximab | 4 | 2 | |
| Abatacept | 1 | 0 | |
| Tofacitinib | 1 | 2 | |
| The median exposure time of a biologic drug (months) | 12.8 (1–95) | 13.0 (1–84) | 0.65 |
| Fever, n | 14 | 28 | 0.01 |
| Myalgia, n | 25 | 9 | 0.37 |
| Cough, n | 19 | 10 | 0.06 |
| Anosmia/ageusia, n | 15 | 0 | 0.03 |
| Diarrhea, n | 9 | 2 | 0.79 |
| Abdominal pain, n | 7 | 2 | 0.94 |
| Dyspnea, n | 4 | 4 | 0.04 |
| Rash, n | 2 | 3 | 0.06 |
| Anorexia/nausea/emesis, n | 3 | 1 | 0.62 |
The statistical significant parameters were presented in bold